Lipocine
LPCN
47 hedge funds and large institutions have $36.5M invested in Lipocine in 2016 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 13 reducing their positions, and 12 closing their positions.
39% more capital invested
Capital invested by funds: $26.2M → $36.5M (+$10.3M)
8% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 13
13% less funds holding
Funds holding: 54 → 47 (-7)
39% less call options, than puts
Call options by funds: $88K | Put options by funds: $144K
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
Top Buyers
| 1 |
RA
Royce & Associates
New York
|
+$1.73M |
| 2 |
JP Morgan Chase
New York
|
+$764K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$297K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$259K |
| 5 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$143K |
Top Sellers
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$1.23M |
| 2 |
AC
Armistice Capital
New York
|
-$1.22M |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$790K |
| 4 |
CC
Carlson Capital
Dallas,
Texas
|
-$328K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$194K |
LPCN Hedge Fund Activity: Q3 2016 in Review
47 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q3 2016, worth a combined $36.5M — up 39% from $26.2M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of LPCN and 6 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 12 added.
The largest buyer was Royce & Associates, adding an estimated $1.73M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $1.23M sold.
- 47 institutional investors held Lipocine (LPCN) as of Q3 2016, down from 54 in Q2 2016.
- Funds reported $36.5M of Lipocine stock for Q3 2016, up 39% quarter-over-quarter.
- 6 funds opened new Lipocine positions in Q3 2016 and 12 closed out, a net change of -6 holders.
- The largest Lipocine buyer in Q3 2016 was Royce & Associates, an estimated $1.73M added.
- The largest Lipocine seller in Q3 2016 was Gilder Gagnon Howe & Co, an estimated $1.23M sold.
Based on aggregated 13F filings for Q3 2016.